MGC begins Phase II study of ArtemiC to treat Covid-19

5th May 2020 (Last Updated May 5th, 2020 11:25)

MGC Pharmaceuticals has started a Phase II clinical trial of ArtemiC for the treatment of patients suffering from Covid-19 infection.

MGC begins Phase II study of ArtemiC to treat Covid-19
The trial will assess the safety and efficacy of the drug in Covid-19 patients. Credit: iXimus from Pixabay.

MGC Pharmaceuticals has started a Phase II clinical trial of ArtemiC for the treatment of patients suffering from Covid-19 infection.

First patients have been enroled at the Nazareth Hospital EMMS in Israel, with treatment scheduled to commence today.

Considered a food supplement, ArtemiC is designed to help address viral infections with inflammatory complications.

MGC said that available scientific data on Artemisinin and Curcumin properties supports the testing of ArtemiC in Covid-19 patients.

The double-blind, placebo-controlled Phase II trial will investigate the safety and efficacy of ArtemiC, a natural formulation intended for immune-modulation.

The aim is to treat the pathophysiological complications of Covid-19.

MGC Pharmaceuticals will conduct the trial in a total of 50 patients at Israel’s Nazareth Hospital EMMS and Hillel Yaffe Hospital, which received human research ethics committee approval last month.

The trial is set to enrol new patients and will start treatment each week, with the study duration being 14 days per patient. Patient enrolment is expected to be completed in September 2020, with data made available in October.

Results will help validate ArtemiC, support design of future trials, and aid commercial discussions that are ongoing for the potential supply and sale of the drug.

The company will carry out research, manufacture and packaging for commercial orders from its operational facilities in Europe. It also has approval to start commercial production.

MGC Pharma co-founder and managing director Roby Zomer said: “This is a very exciting milestone for the company and the trial, and we look forward to updating our shareholders on results as they come to hand.”

The company will own the intellectual property generated from the clinical study.